Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | APEX1 | P27695 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.59 |
| ▸ | TUBB | P07437 | 4/20 | 0.59 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.59 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.59 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.59 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.59 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.59 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.59 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.59 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.59 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.59 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL910429 | 0.87 | TAAR1 (0.65) | CYP3A4CYP1A2TSHRNFKB1LMNA | |
| SCHEMBL910622 | 0.84 | STAT3 (0.60) | CYP3A4CYP1A2CYP19A1 | |
| SCHEMBL11801831 | 0.83 | TSHR (0.63) | CYP3A4CYP1A2TSHRNFKB1MEN1 | |
| SCHEMBL910732 | 0.83 | CYP1A2 (0.62) | CYP3A4CYP1A2TSHRNFKB1MEN1 | |
| SCHEMBL901444 | 0.79 | CYP3A4 (0.71) | CYP3A4CYP1A2TSHRNFKB1MEN1 | |
| SCHEMBL2632685 | 0.79 | TSHR (0.71) | CYP3A4CYP1A2TSHRNFKB1MEN1 | |
| SCHEMBL29833121 | 0.79 | CYP3A4 (0.71) | CYP3A4CYP1A2TSHRNFKB1MEN1 | |
| SCHEMBL1891731 | 0.78 | ALOX15 (0.59) | CYP3A4CYP1A2TSHRNFKB1LMNA | |
| SCHEMBL5181048 | 0.77 | TSHR (0.69) | CYP3A4CYP1A2TSHRNFKB1MEN1 | |
| SCHEMBL21402297 | 0.77 | TSHR (0.69) | CYP3A4CYP1A2TSHRNFKB1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937090-B2 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO COMPANY, LTD. (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | SHISEIDO COMPANY, LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20110004019-A1 | Parakeratosis Inhibitor, Pore-Shrinking Agent, Or Rough Skin Inhibiting/Ameliorating Agent, And External Composition For Skin Containing The Same | SHISEIDO COMPANY LTD. (JP) | 2011-01-06 | — | — | US | disclosed |
| EP-2255780-A1 | PARAKERATOSIS INHIBITOR, PORE SHRINKING AGENT OR AGENT FOR PREVENTING OR IMPROVING ROUGH SKIN, AND COMPOSITION FOR EXTERNAL USE ON THE SKIN CONTAINING THE SAME | Shiseido Company, Ltd. (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-1941861-A1 | WRINKLE-IMPROVING AGENT | Shiseido Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| EP-1880711-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | CYP3A4 4513/4885CYP1A2 3833/4885TSHR 4713/4885 |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | CUTA, AAAS, NUP160 | CYP3A4 4084/4885CYP1A2 3980/4885TSHR 4711/4885 |
| US-20110004019-A1 | Parakeratosis Inhibitor, Pore-Shrinking Agent, Or Rough Skin Inhibiting/Ameliorating Agent, And External Composition For Skin Containing The Same | CUTA, GLRA3, ARGLU1 | CYP3A4 4236/4885CYP1A2 4699/4885TSHR 2401/4885 |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | CYP3A4 4511/4885CYP1A2 3658/4885TSHR 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.